Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

LEVP2006-4 CHANGE 3 Trial (C1-Inhibitor in Hereditary Angioedema Nanofiltration Generation Evaluating Efficacy): Open-Label Use of C1INH-nf (Human) for the Prophylactic Treatment to Prevent HAE Attacks and as Treatment in Acute HAE Attacks

NCT00462709 is registered in ClinicalTrials.gov with Shire as lead sponsor.

NCT NCT00462709
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00462709 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
LEVP2006-4 CHANGE 3 Trial (C1-Inhibitor in Hereditary Angioedema Nanofiltration Generation Evaluating Efficacy): Open-Label Use of C1INH-nf (Human) for the Prophylactic Treatment to Prevent HAE Attacks and as Treatment in Acute HAE Attacks
Lead sponsor
Shire
Phase
Phase 3
Overall status
Completed
Start date
June 27, 2006
Completion date
March 31, 2009
Enrollment
146 (actual)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary angioedema